FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML and Hematologic Malignancies
SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.
Related Articles
VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS
Venetoclax plus azacitidine did not yield an OS benefit vs placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes.
Using Self-Directed Learning to Combat Information Overload in Oncology Fellowship
Jill Gilbert, MD, discusses how principles of adult learning theory can be applied to hematology/oncology fellowship.
Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL
Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.
Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL
The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.
Imatinib Remains Standard of Care in GIST With ‘a Long Way to Go’
Breelyn Wilky, MD, discusses the importance of recognizing GIST Awareness Day and research towards moving the needle in the GIST treatment paradigm.
BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL
BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.
Early Daratumumab in Patients With Myeloma Experiencing MRD Relapse Delays Clinical Progression
PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.
Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.
IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma
The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.
Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML
Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.